Health outcomes and baseline demographics of patients following long-term mepolizumab treatment for ≥3 years at first clinic visit during Part C
| Stopped mepolizumab (N=151) | Continued mepolizumab (N=144) | Total (N=295) | |
| Females, n (%) | 86 (57) | 87 (60) | 173 (59) |
| Age, years, mean (sd) | 55.7 (11.42) | 56.6 (11.53) | 56.1 (11.46) |
| White, n (%) | 125 (83) | 115 (80) | 240 (81) |
| Duration of asthma, years, mean (sd) | 22.8 (13.82) | 25.1 (14.54) | 23.9 (14.20) |
| Blood eosinophil count, cells·µL−1, geometric mean (sd of log) | 40 (0.87) | 50 (0.88) | 50 (0.88) |
| Mepolizumab continuous exposure prior to randomisation at Visit C1 | |||
| Time on mepolizumab, months, median (range) | 44.1 (36–59) | 43.6 (32–58) | 44.1 (32–59) |
| Total exposure, patient-years | 588.0 | 557.2 | 1145.2 |
| Rescue use#, occasions·day−1 BD used, mean (sd) | 0.39 (0.43) | 0.50 (0.45) | 0.44 (0.44) |
| Daily asthma symptom score#, mean (sd)¶ | 1.03 (0.99) | 1.11 (1.04) | 1.07 (1.02) |
| Awakenings at night due to asthma symptoms requiring rescue medication use#, mean (sd) | 0.29 (0.55) | 0.40 (0.73) | 0.34 (0.64) |
| Morning PEF#, L·min−1, mean (sd) | 307 (124) | 296 (117) | 301 (121) |
| Global rating of asthma severity, n (%) | |||
| Clinician | |||
| n | 148 | 144 | 292 |
| Mild | 25 (17) | 18 (13) | 43 (15) |
| Moderate | 60 (41) | 56 (39) | 116 (40) |
| Severe | 52 (35) | 61 (42) | 113 (39) |
| Very severe | 11 (7) | 9 (6) | 20 (7) |
| Patient | |||
| n | 151 | 144 | 295 |
| Mild | 53 (35) | 38 (26) | 91 (31) |
| Moderate | 76 (50) | 72 (50) | 148 (50) |
| Severe | 18 (12) | 28 (19) | 46 (16) |
| Very severe | 4 (3) | 6 (4) | 10 (3) |
BD: bronchodilator; PEF: peak expiratory flow. #Information collected on a daily basis using an eDiary and averaged over the 4-week period prior to the first dose of double-blind treatment. ¶Asthma symptom score evaluated using a 6-point scale of 0 (no symptoms) to 5 (symptoms so severe unable to perform normal daily activities).